Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Resveratrol prevents palmitic acid induced cardiomyocyte contractile impairment.

Lieben Louis X, Raj P, Meikle Z, Yu L, Susser S, MacInnis S, Duhamel TA, Wigle JT, Netticadan T.

Can J Physiol Pharmacol. 2019 Aug 2. doi: 10.1139/cjpp-2019-0051. [Epub ahead of print]

PMID:
31374178
2.

Exercise-induced increases in the expression and activity of cardiac sarcoplasmic reticulum calcium ATPase 2 is attenuated in AMPKα2 kinase-dead mice.

Morissette MP, Susser SE, Stammers AN, Moffatt TL, Wigle JT, Wigle TJ, Netticadan T, Premecz S, Jassal DS, O'Hara KA, Duhamel TA.

Can J Physiol Pharmacol. 2019 Aug;97(8):786-795. doi: 10.1139/cjpp-2018-0737. Epub 2019 Jun 25.

PMID:
31237455
3.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00060-19. doi: 10.1128/JCM.00060-19. Print 2019 Jul.

PMID:
31043467
4.

Oral health, academic performance, and school absenteeism in children and adolescents: A systematic review and meta-analysis.

Ruff RR, Senthi S, Susser SR, Tsutsui A.

J Am Dent Assoc. 2019 Feb;150(2):111-121.e4. doi: 10.1016/j.adaj.2018.09.023. Epub 2018 Nov 23. Review.

PMID:
30473200
5.

Spatial Distribution of Parkinson's Disease Prevalence in Québec by Hydrographic Region.

Susser SR, Gagnon F.

Can J Neurol Sci. 2018 Jul;45(4):478-480. doi: 10.1017/cjn.2018.24.

PMID:
30056823
6.

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy.

Hunyady B, Abonyi M, Gerlei Z, Gervain J, Horváth G, Jancsik V, Lengyel G, Makkai E, Pár A, Péter Z, Pusztay M, Ribiczey P, Rókusz L, Sarrazin C, Schneider F, Susser S, Szalay F, Tornai I, Tusnádi A, Újhelyi E, Werling K, Makara M.

Clin Exp Hepatol. 2018 Jun;4(2):83-90. doi: 10.5114/ceh.2018.75957. Epub 2018 May 25.

7.

Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection.

Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S, Dietz J, Carra G, Finkelmeier F, Grammatikos G, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH.

Aliment Pharmacol Ther. 2018 Jun;47(11):1523-1535. doi: 10.1111/apt.14636. Epub 2018 Apr 10.

PMID:
29637585
8.

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients.

Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C.

J Infect Chemother. 2018 Jul;24(7):524-530. doi: 10.1016/j.jiac.2018.02.008. Epub 2018 Apr 5.

PMID:
29628383
9.

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients.

Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E.

J Infect Dis. 2018 Jun 5;218(1):114-123. doi: 10.1093/infdis/jiy119.

PMID:
29528436
10.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
11.

Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.

Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C.

J Hepatol. 2017 Oct;67(4):680-686. doi: 10.1016/j.jhep.2017.05.027. Epub 2017 Jun 13.

PMID:
28619439
12.

Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M.

J Hepatol. 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. Epub 2016 Dec 10.

PMID:
27965158
13.

Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals.

Kozbial K, Aberle SW, Susser S, Al-Zoairy R, Moser S, Stättermayer AF, Maieron A, Gschwantler M, Stauber R, Graziadei I, Zoller H, Beinhardt S, Holzmann H, Munda-Steindl P, Hofer H, Sarrazin C, Ferenci P.

Aliment Pharmacol Ther. 2017 Jan;45(2):373-375. doi: 10.1111/apt.13887. Epub 2016 Dec 1. No abstract available.

14.

IL28B gene variants and glucose metabolism in Type 2 Diabetes.

Morán-Auth Y, Penna-Martinez M, Perner D, Susser S, Wicker S, Zeuzem S, Sarrazin C, Badenhoop K.

Hum Immunol. 2016 Dec;77(12):1280-1283. doi: 10.1016/j.humimm.2016.09.007. Epub 2016 Sep 21.

PMID:
27664841
15.

Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.

Dietz J, Rupp D, Susser S, Vermehren J, Peiffer KH, Filmann N, Bon D, Kuntzen T, Mauss S, Grammatikos G, Perner D, Berkowski C, Herrmann E, Zeuzem S, Bartenschlager R, Sarrazin C.

PLoS One. 2016 Jun 9;11(6):e0156731. doi: 10.1371/journal.pone.0156731. eCollection 2016.

16.

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.

Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M.

PLoS One. 2015 Dec 23;10(12):e0145622. doi: 10.1371/journal.pone.0145622. eCollection 2015.

17.

Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir.

Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Gilles L, De Locht P, Picchio G, De Meyer S, Sarrazin C.

J Clin Virol. 2015 Nov;72:133-40. doi: 10.1016/j.jcv.2015.09.015. Epub 2015 Oct 8.

PMID:
26513763
18.

Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.

Peiffer KH, Sommer L, Susser S, Vermehren J, Herrmann E, Döring M, Dietz J, Perner D, Berkowski C, Zeuzem S, Sarrazin C.

Hepatology. 2016 Jan;63(1):63-73. doi: 10.1002/hep.28255. Epub 2015 Nov 25.

PMID:
26406534
19.

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.

Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C.

PLoS One. 2015 Aug 28;10(8):e0134395. doi: 10.1371/journal.pone.0134395. eCollection 2015.

20.

The regulation of sarco(endo)plasmic reticulum calcium-ATPases (SERCA).

Stammers AN, Susser SE, Hamm NC, Hlynsky MW, Kimber DE, Kehler DS, Duhamel TA.

Can J Physiol Pharmacol. 2015 Oct;93(10):843-54. doi: 10.1139/cjpp-2014-0463. Epub 2015 Jan 19. Review.

PMID:
25730320
21.

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.

Susser S, Flinders M, Reesink HW, Zeuzem S, Lawyer G, Ghys A, Van Eygen V, Witek J, De Meyer S, Sarrazin C.

Antimicrob Agents Chemother. 2015 May;59(5):2746-55. doi: 10.1128/AAC.04911-14. Epub 2015 Feb 23.

22.

Cardiovascular complications of type 2 diabetes in youth.

Kehler DS, Stammers AN, Susser SE, Hamm NC, Kimber DE, Hlynsky MW, Duhamel TA.

Biochem Cell Biol. 2015 Oct;93(5):496-510. doi: 10.1139/bcb-2014-0118. Epub 2014 Dec 7. Review.

PMID:
25629355
23.

Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.

Welsch C, Haselow K, Gouttenoire J, Schneider M, Morikawa K, Martinez Y, Susser S, Sarrazin C, Zeuzem S, Antes I, Moradpour D, Lange CM.

J Hepatol. 2015 Apr;62(4):779-84. doi: 10.1016/j.jhep.2014.11.009. Epub 2014 Nov 21.

PMID:
25463536
24.

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.

Susser S, Herrmann E, Lange C, Hamdi N, Müller T, Berg T, Perner D, Zeuzem S, Sarrazin C.

PLoS One. 2014 Nov 13;9(11):e112592. doi: 10.1371/journal.pone.0112592. eCollection 2014.

25.

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.

Maasoumy B, Hunyady B, Calvaruso V, Makara M, Vermehren J, Haragh A, Susser S, Bremer B, Cloherty G, Manns MP, Craxì A, Wedemeyer H, Sarrazin C.

PLoS One. 2014 Nov 12;9(11):e110857. doi: 10.1371/journal.pone.0110857. eCollection 2014.

26.

Differential regulation of the fiber type-specific gene expression of the sarcoplasmic reticulum calcium-ATPase isoforms induced by exercise training.

Morissette MP, Susser SE, Stammers AN, O'Hara KA, Gardiner PF, Sheppard P, Moffatt TL, Duhamel TA.

J Appl Physiol (1985). 2014 Sep 1;117(5):544-55. doi: 10.1152/japplphysiol.00092.2014. Epub 2014 May 29.

27.

HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy.

Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Picchio G, Sarrazin C.

Antivir Ther. 2014;19(6):559-67. doi: 10.3851/IMP2760. Epub 2014 Feb 28.

PMID:
24584086
28.

Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients.

Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Penna-Martinez M, Badenhoop K, Zeuzem S, Berg T, Sarrazin C.

PLoS One. 2014 Feb 7;9(2):e87974. doi: 10.1371/journal.pone.0087974. eCollection 2014.

29.

Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.

Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, Zeuzem S, Colombo M, Weiland O, Sarrazin C.

J Hepatol. 2014 May;60(5):913-9. doi: 10.1016/j.jhep.2014.01.002. Epub 2014 Jan 11.

PMID:
24424305
30.

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection.

Fischer J, Böhm S, Müller T, Witt H, Sarrazin C, Susser S, Migaud P, Schott E, Stewart G, Brodzinski A, Fülöp B, van Bömmel F, George J, Berg T.

PLoS One. 2013 Oct 29;8(10):e77530. doi: 10.1371/journal.pone.0077530. eCollection 2013.

31.

Suicide following an infestation of bed bugs.

Burrows S, Perron S, Susser S.

Am J Case Rep. 2013 May 29;14:176-8. doi: 10.12659/AJCR.883926. Print 2013.

32.

Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.

Vermehren A, Welsch C, Elsler U, Vermehren J, Herrmann E, Sarrazin C, von Wagner M, Susser S, Hofmann WP, Kronenberger B, Zeuzem S, Mihm U.

Antivir Ther. 2013;18(6):803-11. doi: 10.3851/IMP2663. Epub 2013 Jul 3.

PMID:
23824381
33.

Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.

Köberle V, Waidmann O, Kronenberger B, Andrei A, Susser S, Füller C, Perner D, Zeuzem S, Sarrazin C, Piiper A.

J Viral Hepat. 2013 Aug;20(8):530-5. doi: 10.1111/jvh.12075. Epub 2013 Feb 18.

PMID:
23808991
34.

Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.

Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, Füller C, Däumer M, Teuber G, Wedemeyer H, Berg T, Lengauer T, Zeuzem S, Herrmann E, Sarrazin C.

J Virol. 2013 Jun;87(11):6172-81. doi: 10.1128/JVI.02778-12. Epub 2013 Mar 27.

35.

Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs.

Peveling-Oberhag J, Herrmann E, Kronenberger B, Farnik H, Susser S, Sarrazin C, Zeuzem S, Hofmann WP.

J Viral Hepat. 2013 Apr;20(4):234-9. doi: 10.1111/jvh.12013. Epub 2012 Nov 15.

PMID:
23490367
36.

Exercise training prevents the development of cardiac dysfunction in the low-dose streptozotocin diabetic rats fed a high-fat diet.

Epp RA, Susser SE, Morissette MP, Kehler DS, Jassal DS, Duhamel TA.

Can J Physiol Pharmacol. 2013 Jan;91(1):80-9. doi: 10.1139/cjpp-2012-0294. Epub 2012 Oct 26.

PMID:
23369057
37.

Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design.

Zitzer H, Heilek G, Truchon K, Susser S, Vermehren J, Sizmann D, Cobb B, Sarrazin C.

J Clin Microbiol. 2013 Feb;51(2):571-7. doi: 10.1128/JCM.01784-12. Epub 2012 Dec 12.

38.

Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper.

Welker MW, Susser S, Welsch C, Perner D, Füller C, Kronenberger B, Herrmann E, Zeuzem S, Sarrazin C.

J Viral Hepat. 2012 Nov;19(11):775-83. doi: 10.1111/j.1365-2893.2012.01605.x. Epub 2012 Apr 1.

PMID:
23043384
39.

Mental health effects from urban bed bug infestation (Cimex lectularius L.): a cross-sectional study.

Susser SR, Perron S, Fournier M, Jacques L, Denis G, Tessier F, Roberge P.

BMJ Open. 2012 Sep 25;2(5). pii: e000838. doi: 10.1136/bmjopen-2012-000838. Print 2012.

40.

Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.

Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C.

J Clin Virol. 2012 Sep;55(1):17-22. doi: 10.1016/j.jcv.2012.05.008. Epub 2012 Jun 13.

PMID:
22698697
41.

A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers.

Vermehren J, Lötsch J, Susser S, Wicker S, Berger A, Zeuzem S, Sarrazin C, Doehring A.

PLoS One. 2012;7(3):e32605. doi: 10.1371/journal.pone.0032605. Epub 2012 Mar 20.

42.

Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity.

Welker MW, Reichert D, Susser S, Sarrazin C, Martinez Y, Herrmann E, Zeuzem S, Piiper A, Kronenberger B.

PLoS One. 2012;7(2):e30796. doi: 10.1371/journal.pone.0030796. Epub 2012 Feb 15.

43.

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.

Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarrazin C.

J Viral Hepat. 2012 Feb;19(2):120-7. doi: 10.1111/j.1365-2893.2011.01449.x. Epub 2011 Mar 1.

PMID:
22239501
44.

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.

Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T.

Hepatology. 2012 Jun;55(6):1700-10. doi: 10.1002/hep.25582. Epub 2012 Apr 18.

PMID:
22234924
45.

Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma.

Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A.

PLoS One. 2011;6(10):e26971. doi: 10.1371/journal.pone.0026971. Epub 2011 Oct 31.

46.

Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.

Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Nájera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD.

Antimicrob Agents Chemother. 2012 Jan;56(1):271-9. doi: 10.1128/AAC.05636-11. Epub 2011 Nov 7.

47.

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.

Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, Zeuzem S, Sarrazin C.

J Clin Virol. 2011 Dec;52(4):321-7. doi: 10.1016/j.jcv.2011.08.015. Epub 2011 Sep 15.

PMID:
21924672
48.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
49.

HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.

Lange CM, Susser S, Herrmann E, Karey U, Kieffer TL, Kwong AD, Schinkel J, Reesink HW, Zeuzem S, Sarrazin C.

Scand J Gastroenterol. 2011 Nov;46(11):1362-8. doi: 10.3109/00365521.2011.605465. Epub 2011 Aug 5.

PMID:
21815864
50.

Screening for IL28B gene variants identifies predictors of hepatitis C therapy success.

Doehring A, Hofmann WP, Schlecker C, Zeuzem S, Susser S, Geisslinger G, Sarrazin C, Lötsch J.

Antivir Ther. 2010;15(8):1099-106. doi: 10.3851/IMP1689.

PMID:
21149916

Supplemental Content

Loading ...
Support Center